Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

HER2 Status And Disparities In Luminal Breast Cancers

Andreana N Holowatyj, J. Ruterbusch, M. Ratnam, D. Gorski, M. Cote
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
National Comprehensive Care Network guidelines for adjuvant treatment of invasive breast cancer are based on HER2 and hormone receptor (HR) status, where HR+ disease encompasses all estrogen receptor (ER)+ and/or progesterone receptor (PR)+ tumors. We sought to explore clinical and demographic differences among patients with HR+ breast cancer subtypes, and the role of HER2 status, age, race/ethnicity, and socioeconomic status (SES) in disease risk. We evaluated breast cancer subtype distribution, defined by HR and HER2 status, using patient clinical, demographic, and socioeconomic characteristics. Differences in HR categories by demographic and tumor characteristics were examined using chi‐squared tests. Multinomial logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) to quantify associations between breast cancer HR status and demographic factors. We found that differences in HR+ (ER−/PR+ vs. ER+/PR− or ER+/PR+) tumor biology are likely clinically significant and may play a role in breast cancer, regardless of HER2 status. While clinical and patient characteristics differed within each luminal subtype, we found disparities in SES only among Luminal A (HR+/HER2−) tumors. Among HR+/HER2− cases, we observed that ER−/PR+ patients tend to live in areas of higher poverty (OR = 1.20, 95% CI = 1.03–1.40) and are 70% more likely to be aged 50 years or older. However, this pattern was not found in women with Luminal B (HR+/HER2+) disease (Poverty OR = 0.98, 95% CI = 0.76–1.27; Age OR = 1.01, 95% CI = 0.81–1.26). Racial/ethnic disparities among non‐Hispanic black and Hispanic women persisted across HR+/HER2− cases compared to non‐Hispanic white women. Our findings suggest that while race/ethnicity and SES are correlated, each plays an independent role in contributing to disease among Luminal A tumors. Further study is needed to investigate how tumor biology, race/ethnicity, and socioeconomic disparities among HR+/HER2− cases may contribute to poorer patient prognosis.
This paper references
10.3322/canjclin.39.6.399
Cancer statistics
N. Dubrawsky (1989)
10.1158/0008-5472.CAN-12-3349
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.
S. Ithimakin (2013)
10.1371/journal.pmed.1000279
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
F. Blows (2010)
10.1093/jncimonographs/lgu020
Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) Registries.
J. Kish (2014)
10.1007/s12672-013-0158-6
Progesterone Decreases Levels of the Adhesion Protein E-Cadherin and Promotes Invasiveness of Steroid Receptor Positive Breast Cancers
A. Kariagina (2013)
Oestrogen signalling A. N. Holowatyj et al. HER2 and Disparities in Luminal Breast Cancers inhibits invasive phenotype by repressing RelB and its target BCL2
X Wang (2007)
10.3322/caac.21332
Cancer statistics, 2016
Rebecca L. Siegel Mph (2016)
10.18632/oncotarget.5082
Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges
T. McFall (2015)
The influence of socioeconomic status on racial/ethnic disparities among the ER/PR/HER2 breast cancer
C. A. Parise (2015)
J. Clin. Oncol
Effect of progesterone on the invasive properties and tumor growth of progesterone receptortransfected breast cancer cells
V. C. Lin (2001)
10.3322/caac.21332
Cancer statistics, 2016
R. Siegel (2016)
10.1186/s40064-015-1282-2
Socioeconomic status and incidence of breast cancer by hormone receptor subtype
T. Akinyemiju (2015)
10.1007/s10549-015-3474-4
Race-associated biological differences among Luminal A breast tumors
Monica D’arcy (2015)
10.1016/S0960-0760(03)00364-9
Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators
J. Geisler (2003)
10.1038/ncb1559
Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2
X. Wang (2007)
10.1007/s10549-014-2976-9
Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010–2011)
Helmneh M. Sineshaw (2014)
J. Steroid Biochem. Mol. Biol
10.1093/jnci/dju055
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
N. Howlader (2014)
10.1093/OXFORDJOURNALS.AJE.A009114
Explaining the relation between education and postmenopausal breast cancer.
K. Heck (1997)
10.1093/jnci/dju237
Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium.
J. Palmer (2014)
SEER Cancer Statistics Review, 1975-2003
L. Ries (2006)
Available at: http://seer.cancer.gov/ csr/1975_2012/. Based on November 2014 SEER data submission, posted to the SEER web site
N Howlader (1973)
10.1210/JCEM.81.4.8636351
Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients.
J. Pasqualini (1996)
Oestrogen signalling © 2016 The Authors
X Wang (2007)
10.1200/JCO.2009.24.9284
Breast cancer subtypes and the risk of local and regional relapse.
K. D. Voduc (2010)
10.1155/2015/813456
The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes
C. Parise (2015)
10.1007/s10552-012-9966-1
Socioeconomic disparities and breast cancer hormone receptor status
Abegail A. Andaya (2012)
Oestrogen signalling
X. Wang (2007)
National Comprehensive Care Network Breast cancer. NCCN Clinical Practice Guidelines in Oncology
(2015)
HER2 and Disparities in Luminal Breast Cancers inhibits invasive phenotype by repressing RelB and its target BCL2
A N Holowatyj
Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231.
V. C. Lin (2001)
10.1007/s10549-010-0827-x
Health disparities in breast cancer: biology meets socioeconomic status
B. Dunn (2010)
Breast cancer. NCCN Clinical Practice Guidelines in Oncology
(2015)
NCCN breast cancer clinical practice guidelines in oncology: an update.
R. Carlson (2003)
10.1101/cshperspect.a003293
Systems biology and genomics of breast cancer.
C. Perou (2011)
10.1007/s10549-012-2142-1
Breast cancer characteristics and outcomes among Hispanic Black and Hispanic White women
Matthew P Banegas (2012)
10.1158/1078-0432.CCR-10-1533
Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study
K. O'Brien (2010)
varying) -Linked To County Attributes -Total U.S., 1969-2011 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch
(1973)
10.1700/363.4228
Factors predictive of response to hormone therapy in breast cancer.
F. Rastelli (2008)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar